In-vitro inhibition of leucocyte migration by sarcoid spleen suspension in coeliac disease and dermatitis herpetiformis

Novel Naturally Occurring Dipeptides and Single-Stranded Oligonucleotide Act as Entry Inhibitors and Exhibit a Strong Synergistic Anti-HIV-1 Profile

Introduction

The availability of new classes of antiretroviral drugs is critical for treatment-experienced patients due to drug resistance to and unwanted side effects from current drugs. Our aim was therefore to evaluate the anti-HIV-1 activity of a new set of antivirals, dipeptides (WG-am or VQ-am) combined with a single-stranded oligonucleotide (ssON). The dipeptides were identified as naturally occurring and enriched in feces and systemic circulation in HIV-1-infected elite controllers and were proposed to act as entry inhibitors by binding to HIV-1 gp120. The ssON is DNA 35-mer, stabilized by phosphorothioate modifications, which acts on the endocytic step by binding to cell host receptors and inhibiting viruses through interference with binding to nucleolin.

Methods

Chou–Talalay’s Combination Index method for quantifying synergism was used to evaluate the drug combinations. Patient-derived chimeric viruses encoding the gp120 (env region) were produced by transient transfection and used to evaluate the antiviral profile of the combinations by drug susceptibility assays.

Results

We found that the combination WG-am:ssON or VQ-am:ssON had low combination index values, suggesting strong antiviral synergism. Of the two combinations, WG-am:ssON (1 mM:1 μM) had high efficacy against all prototype or patient-derived HIV-1 isolates tested, independent of subtype including the HIV-1-A6 sub-subtype. In addition, the antiviral effect was independent of co-receptor usage in patient-derived strains.

Conclusion

WG-am and ssON alone significantly inhibited HIV-1 replication regardless of viral subtype and co-receptor usage, and the combination WG-am:ssON (1 mM:1 μM) was even more effective due to synergism.

A Rare Comorbidity: Dermatitis Herpetiformis and Sarcoidosis - A Case Report

Sarcoidosis is an enigmatic, multisystem granulomatous disease of unknown etiology and wide range of clinical presentations. Case report: A 54-year-old female presented with facial rash: polymorphic, round, infiltrated erythematous plaques, 1 - 3 cm in size, disseminated on several areas of the face. The medical history was consistent with dermatitis herpetiformis and persistent intrahepatic cholestasis. The laboratory test results suggested celiac disease (strong positivity of IgA anti-tissue transglutaminase antibodies) but upper endoscopy was not performed to confirm it. The skin biopsy revealed noncaseating epithelioid-cell granulomas, and negative direct immunofluorescence showed IgA deposits in the dermis. Sarcoidosis with cutaneous and hepatic involvement was established based on compatible clinical findings and supportive histology. The period between manifestations of Duhring disease and skin manifestations of sarcoidosis was 20 years. Conclusion: Our clinical case supports the hypothesis for common immune pathogenic factors in gluten-sensitive diseases and sarcoidosis. The simultaneous occurrence of celiac disease and sarcoidosis is rare, but should not be under recognized.

Leukocyte migration agarose test (LMAT) in sarcoidosis using Kveim test material

The two-stage leukocyte migration agarose test (indirect LMAT), shown to be a sensitive in vitro assay for cell-mediated immunity, was used to study Kveim reactivity in vitro in patients with sarcoidosis. No Kveim-induced inhibition of leukocyte migration in agarose or Kveim-induced lymphocyte transformation in vitro was found in 23 patients with sarcoidosis, suggesting that the Kveim reaction is not an expression of cell-mediated immunity.

Comparative in vitro reactivities of leukocytes from sarcoids and normals to different Kveim preparations

Comparative studies of in vivo and in vitro reactivities to Kveim preparations have been carried out in 45 sarcoid and 30 normal subjects. Lymphocytes of 14 of 45 sarcoids and 4 of 30 normals proliferated significantly in response to at least 1 of the 4 Kveim suspensions used for in vitro studies. The prevalence of positive responses were significantly greater in sarcoids than normals in cultures containing Kveim-CSL and Kveim-Edinburgh. The Kveim-reactive cells were less stimulated by PHA, but no other significant alterations were found, including the presence or absence of in vivo Kveim reactivity in the cell donors. Reactivity to more than 1 Kveim preparation occurred in 9 of 14 cases. Kveim-induced leukocyte migration inhibition occurred more commonly in sarcoids than normals, but differences were not as striking. There was not a precise correlation between proliferative and migration-inhibition responses to Kveim.

Coeliac disease and autoimmunity

Among fifty-seven patients with proven coeliac disease three also had thyrotoxicosis, two insulin dependant diabetes, three fibrosing alveolitis and one each had vitiligo, rheumatoid arthritis and cryptogenic cirrhosis. Autoantibodies were demonstrated in twelve of thirty-one patients tested, seven of these twelve had one of the above associated conditions. Antireticulin antibodies were found in seven of twenty-three patients tested, and there was a significant association with dietary gluten. These findings appear to support that coeliac disease is associated with disturbed immunity and that a predisposition to autoimmunity may exist.

The Kmif (Kveim-induced macrophage migration inhibition factor) test in sarcoidosis

Circulating lymphocytes from 30 patients with sarcoidosis when stimulated in vitro with Kveim-induced macrophage migration factor, the Kmif test, produced a guinea-pig macrophage migration inhibition factor in 21 of 30 cases (70%). In those patients not on steroids the results showed a good correlation with the cutaneous Kveim test. One positive test was found in 16 normal subjects. Our results suggest that the Kmif test may prove a useful rapid alternative to the Kveim test.